One dose, once a month, designed to work 24/7 to help prevent migraine in adults1,2

Aimovig® offers the flexibility of 2 different dosing options1

dosing-1
  • The recommended dosage of Aimovig® is 70 mg once monthly; some patients may benefit from 140 mg once monthly1
  • No loading dose1
  • No dose adjustment required for special populations1
  • Hidden 27-guage needle3
  • Doses may be administered subcutaneously in the upper arm, thigh, or abdomen1,*
*Administration in the upper arm requires a caregiver to inject.1

In a usability study of the SureClick® autoinjector among adult migraine patients (N = 204)4,†:

dosing-2 found the autoinjector
easy to use
and
dosing-3 would recommend the autoinjector to other patients
204 autoinjector-naïve adult migraine patients were evaluated in a usability study of the Aimovig SureClick® single-dose autoinjector by performing a simulated injection. Percentage was derived from a combination of patients who stated completely agree or somewhat agree on a 5-point Likert scale.4

The AHS recommends assessing the benefits of anti-CGRP mAb therapy after 3 months of treatment for those administered monthly.5

*Administration in the upper arm requires a caregiver to inject.1

204 autoinjector-naïve adult migraine patients were evaluated in a usability study of the Aimovig SureClick® single-dose autoinjector by performing a simulated injection. Percentage was derived from a combination of patients who stated completely agree or somewhat agree on a 5-point Likert scale.4

Show your patients this overview video on injecting Aimovig®

It is important that you thoroughly review the Instructions for Use. The 70 mg and 140 mg instructions cover everything you need to know about how to use the Aimovig SureClick® autoinjector. The information on this website does not replace the Instructions for Use.

AHS = American Headache Society; CGRP = calcitonin gene-related peptide; mAb = monoclonal antibody.